Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
465 studies found for:    Open Studies | "Multiple Myeloma"
Show Display Options
Rank Status Study
21 Recruiting Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: blood samples;   Biological: Bone marow samples
22 Recruiting An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
Condition: Multiple Myeloma
Intervention:
23 Recruiting Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
24 Recruiting Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Clarithromycin;   Drug: Thalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
25 Recruiting Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
26 Recruiting Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Metformin XR;   Drug: Dexamethasone
27 Available Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
28 Recruiting Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Condition: Multiple Myeloma
Interventions: Drug: plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
29 Recruiting Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Intervention: Drug: Melphalan HCl for injection (propylene glycol free)
30 Not yet recruiting A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Dexamethasone
31 Recruiting Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Condition: Multiple Myeloma
Interventions: Biological: Pembrolizumab;   Drug: Pomalidomide;   Drug: Dexamethasone
32 Recruiting A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab Subcutaneous (SC) Administration;   Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC infusion
33 Recruiting Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Donor Bone Marrow stem cell transplantation
34 Recruiting A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
Condition: Multiple Myeloma
Interventions: Drug: Venetoclax;   Drug: ABBV-838;   Drug: Dexamethasone
35 Recruiting Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: I-131-CLR1404;   Drug: dexamethasone
36 Recruiting Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Liposomal doxorubicin;   Drug: Dexamethasone
37 Recruiting Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Prednisone;   Drug: Methylprednisolone
38 Recruiting A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma
Interventions: Drug: DARATUMUMAB;   Drug: DURVALUMAB
39 Recruiting Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Oprozomib formulation 1;   Drug: Oprozomib formulation 2;   Drug: Dexamethasone;   Drug: Pomalidomide
40 Recruiting Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.